Conference Coverage

VIDEO: Genomics, other advances further highlight how breast cancer differs in men


 

AT MBCC

MIAMI BEACH – Growing evidence continues to point to a widening separation between female and male breast cancers, particularly with discoveries suggesting different pathways to disease and important genetic distinctions.

Therefore, the traditional practice of extrapolating findings from female breast cancer research to men with breast cancer no longer makes sense, Patrick I. Borgen, MD, said at the annual Miami Breast Cancer Conference, held by Physicians’ Education Resource.

The incidence of male breast cancer is increasing. At the same time, fewer men with breast cancer get referred for and undergo genetic testing for their disease, said Dr. Borgen, chair of the department of surgery at Maimonides Medical Center in Brooklyn, N.Y.

Dr. Borgen explained in a video interview that both maternal and paternal inheritance of breast cancer are important, and they tie the lineage into a hypothesis for why BRCA mutations – which can predispose people to worse survival – have persisted through generations.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Dr. Borgen is a member of the speakers bureau for Genomic Health Inc., NanoString Technologies, Genentech, and Pacira Inc.

Recommended Reading

Posttreatment survivorship care needs of Spanish-speaking Latinas with breast cancer
MDedge Hematology and Oncology
VIDEO: Resistance to endocrine therapy a moving target
MDedge Hematology and Oncology
VIDEO: Breast surgeons can and do provide genetic counseling to cancer patients
MDedge Hematology and Oncology
VIDEO: Future therapies look promising for HER2 treatment-resistant breast cancer patients
MDedge Hematology and Oncology
VIDEO: HER2+ patients may do fine with local therapies alone
MDedge Hematology and Oncology
VIDEO: Registry studies reflect real patients in the real world
MDedge Hematology and Oncology
VIDEO: Vaccines, combination therapy hold most promise for optimizing immunotherapy in breast cancer
MDedge Hematology and Oncology
VIDEO: What’s new with HER2-neu inhibition
MDedge Hematology and Oncology
VIDEO: Multiple PARP inhibitors show promise in breast cancer treatment
MDedge Hematology and Oncology
VIDEO: It’s too early to give up on immunotherapy for breast cancer
MDedge Hematology and Oncology